Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
Navigating Presbyopia Conversations with Patients in Practice
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > Topical cenegermin induces sustained epithelial healing in eyes with neurotrophic keratopathy
  • Neurotrophic Keratitis

Topical cenegermin induces sustained epithelial healing in eyes with neurotrophic keratopathy

Kelsey Moroz

Olivia Lee, MD, professor at University of California Irvine Gavin Herbert Eye Institute, spoke with Ophthalmology 360 at the American Society of Cataract and Refractive Surgery Annual Meeting about a study that found cenegermin improves corneal sensation and corneal nerve regeneration in the first 8 weeks of treatment.

Olivia Lee, MD:

Our study looked at patients that I treated with neurotrophic keratitis with Oxervate and followed these patients long-term over a 12 month period of time. I included patients with macular stages 1, 2, and 3 without any prior corneal surgery.

Our findings showed that the greatest improvement in corneal sensation and corneal nerve regeneration happens in the first 8 weeks. In other words, during the course of treatment. That improvement plateaus but remains the same and is sustained till the 12-month mark. Of our 28 patients that we followed for 12 months, we saw a statistically significant improvement in corneal sensation as measured by Cochet-Bonnet, as well as corneal nerve density, epithelial cell density by in vivo confocal microscopy over the 12-month period of time.

It means that you treat the patient with 1 course of Oxervate, if they improve during that course, you can expect that that improvement is sustained over a 1-year period of time as compared to baseline.

Share

Related Content

  • Presbyopia

How to integrate presbyopia care into your practice

  • Presbyopia

Yuvezzi is the newest treatment option for presbyopia: MD/OD panel reacts

  • Presbyopia

Presbyopia-correcting drops have changed the field for patients

  • Presbyopia

Presbyopia makes a frustrating impact on patients’ lives

  • Presbyopia

Navigating presbyopia conversations with patients in practice

  • Practice Management

AOA 2026: What is the best IOL for my patient?

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon